{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:45:49Z","timestamp":1792691149845,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ejps.2024.106765","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T06:56:59Z","timestamp":1712732219000},"page":"106765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Absorption of cinnarizine from type II lipid-based formulations: Impact of lipid chain length, supersaturation, digestion, and precipitation inhibition"],"prefix":"10.1016","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1323-6891","authenticated-orcid":false,"given":"Felix","family":"Paulus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jef","family":"Stappaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-6984","authenticated-orcid":false,"given":"Annette","family":"Bauer-Brandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106765_bib0001","first-page":"11","article-title":"Chemical and related factors controlling lipid solubility","volume":"92","author":"Anderson","year":"1999","journal-title":"Bulletin Technique Gattefoss\u00e9"},{"key":"10.1016\/j.ejps.2024.106765_bib0002","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejpb.2017.05.001","article-title":"Simultaneous lipolysis\/permeation in vitro model, for the estimation of bioavailability of lipid based drug delivery systems","volume":"117","author":"Bibi","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.ejps.2024.106765_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejps.2013.04.002","article-title":"Biopharmaceutical classification of poorly soluble drugs with respect to \u201cenabling formulations","volume":"50","author":"Buckley","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2024.106765_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijpharm.2003.10.036","article-title":"Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility","volume":"270","author":"de Smidt","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2024.106765_bib0004","unstructured":"FDA. (2010). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020766s028lbl.pdf (accessed on 30 January 2023)."},{"key":"10.1016\/j.ejps.2024.106765_bib0006","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jconrel.2014.07.037","article-title":"\u2018Stealth'lipid-based formulations: poly (ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug","volume":"192","author":"Feeney","year":"2014","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejps.2024.106765_bib0005","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.addr.2016.04.007","article-title":"50 years of oral lipid-based formulations: provenance, progress and future perspectives","volume":"101","author":"Feeney","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2024.106765_bib0008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejpb.2016.01.007","article-title":"Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats","volume":"101","author":"Holm","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2024.106765_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106556","article-title":"Lipid based formulations as supersaturating oral delivery systems: from current to future industrial applications","volume":"189","author":"Holm","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106765_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105452","article-title":"Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapad\u24c7 membrane and in vivo absorption","volume":"152","author":"Ilie","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2024.106765_bib0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/03639045.2020.1721526","article-title":"Supersaturated lipid-based drug delivery systems\u2013exploring impact of lipid composition type and drug properties on supersaturability and physical stability","volume":"46","author":"Ilie","year":"2020","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2024.106765_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105691","article-title":"Exploring precipitation inhibitors to improve in vivo absorption of cinnarizine from supersaturated lipid-based drug delivery systems","volume":"159","author":"Ilie","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2024.106765_bib0012","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/pharmaceutics15020592","article-title":"Commercially available cell-free permeability tests for industrial drug development: increased sustainability through reduction of in vivo studies","volume":"15","author":"Jacobsen","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2024.106765_bib0013","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/B:PHAM.0000016282.77887.1f","article-title":"Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations","volume":"21","author":"Kaukonen","year":"2004","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejps.2024.106765_bib0014","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jps.23384","article-title":"The effect of administered dose of lipid-based formulations on the in vitro and in vivo performance of cinnarizine as a model poorly water-soluble drug","volume":"102","author":"Lee","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"1\u20133","key":"10.1016\/j.ejps.2024.106765_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2024.106765_bib0017","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1208\/s12248-015-9832-7","article-title":"The effect of digestion and drug load on halofantrine absorption from self-nanoemulsifying drug delivery system (SNEDDS)","volume":"18","author":"Michaelsen","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2024.106765_bib0016","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejpb.2019.07.002","article-title":"Fenofibrate oral absorption from SNEDDS and super-SNEDDS is not significantly affected by lipase inhibition in rats","volume":"142","author":"Michaelsen","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2024.106765_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121958","article-title":"Controlling drug release by introducing lipase inhibitor within a lipid formulation","volume":"623","author":"Murshed","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2024.106765_bib0019","article-title":"Digestion is a critical element for absorption of cinnarizine from supersaturated lipid-based type I formulations","author":"Paulus","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106765_bib0020","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0928-0987(00)00167-6","article-title":"Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and \u2018self-microemulsifying\u2019 drug delivery systems","volume":"11","author":"Pouton","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3\u20134","key":"10.1016\/j.ejps.2024.106765_bib0021","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejps.2006.04.016","article-title":"Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system","volume":"29","author":"Pouton","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.ejps.2024.106765_bib0022","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1002\/jps.22226","article-title":"Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate","volume":"99","author":"Sassene","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2024.106765_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1211\/0022357021771896","article-title":"Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products","volume":"54","author":"Sek","year":"2002","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106765_bib0025","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1208\/s12248-012-9398-6","article-title":"Characterising lipid lipolysis and its implication in lipid-based formulation development","volume":"14","author":"Thomas","year":"2012","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.ejps.2024.106765_bib0024","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2012.02.027","article-title":"In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS)","volume":"160","author":"Thomas","year":"2012","journal-title":"J. Controlled Release"},{"issue":"9","key":"10.1016\/j.ejps.2024.106765_bib0026","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1002\/jps.23205","article-title":"Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations","volume":"101","author":"Williams","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.ejps.2024.106765_bib0027","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1248\/cpb.13.1279","article-title":"Biopharmaceutical studies on factors affecting rate of absorption of drugs. I. Absorption of salicylamide in micellar solution","volume":"13","author":"Yamada","year":"1965","journal-title":"Chem. Pharm. Bull."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T11:29:12Z","timestamp":1715081352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724000769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":28,"alternative-id":["S0928098724000769"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106765","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absorption of cinnarizine from type II lipid-based formulations: Impact of lipid chain length, supersaturation, digestion, and precipitation inhibition","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106765","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106765"}}